Literature DB >> 8882610

Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.

M Vázquez1, M Merlos, T Adzet, J C Laguna.   

Abstract

1. The effect of clofibrate (CFB), bezafibrate (BFB), and gemfibrozil (GFB) on plasma lipoprotein (VLDL and LDL) concentration, composition and resistance to copper-induced oxidation has been studied in male Sprague-Dawley rats after a 15 day treatment. 2. Plasma triglyceride levels were reduced by CFB (41%) and BFB (39%). This effect was related to a significant reduction (67% for CFB and 56% for BFB) in the amount of circulating VLDL-protein. 3. Plasma total cholesterol was reduced by 28% and 45% in CFB- and BFB-treated animals, respectively, mainly by modification of the cholesteryl ester fraction. In contrast, GFB significantly increased total cholesterol (27%). No modification in the LDL protein or lipid content was introduced by fibrates, although GFB decreased the proportion of LDL-triglycerides, at the expense of an increase in total cholesterol. 4. The fatty acid species carried by VLDL and LDL were affected after fibrate treatment. In general, both particles showed an increase in monounsaturated fatty acids (MUFA) (18:1) and a decrease in polyunsaturated fatty acids (PUFA) species (18:2 n-6, 20:4 n-6, 18:3 n-3, 20:5 n-3). As a consequence, the ratio of PUFA/(SFA+MUFA) for the whole lipoproteins was markedly reduced. 5. The degree of copper-induced VLDL- and LDL-oxidation was assessed by means of the analysis of lysine content, thiobarbituric acid reactive substances (TBARS) production and conjugated dienes formation. Lipoproteins obtained from fibrate-treated rats were more resistant to the oxidative challenge. For each lipoprotein, BFB was the most effective drug, followed by CFB and GFB. 6. The observed antioxidant effect can be ascribed to two independent phenomena produced by fibrates: the reduction of the amount of substrate for the oxidation process due to their hypolipidemic activity, and the alteration in the type of fatty acids transported by the lipoproteins towards an enrichment in species resistant to the oxidation process. 7. As similar lipoprotein fatty acid changes have been reported after fibrate treatment in human subjects, an antioxidant effect of fibrates in human therapy, independent of their well known hypolipidaemic activity, should be expected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882610      PMCID: PMC1909812          DOI: 10.1111/j.1476-5381.1996.tb16710.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  THE EFFECTS OF ETHYL CHLOROPHENOXYISOBUTYRATE ON SERUM CHOLESTERYL, TRIGLYCERIDE AND PHOSPHOLIPID FATTY ACIDS.

Authors:  J JURAND; M F OLIVER
Journal:  J Atheroscler Res       Date:  1963 Sep-Dec

Review 2.  Lipoprotein assembly and secretion by hepatocytes.

Authors:  J E Vance; D E Vance
Journal:  Annu Rev Nutr       Date:  1990       Impact factor: 11.848

3.  The effect of clofibrate on vitamin E concentrations in the rat.

Authors:  P Weiss; J R Bianchine
Journal:  Atherosclerosis       Date:  1970 Mar-Apr       Impact factor: 5.162

Review 4.  The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney.

Authors:  J M Hawkins; W E Jones; F W Bonner; G G Gibson
Journal:  Drug Metab Rev       Date:  1987       Impact factor: 4.518

5.  Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.

Authors:  B Vessby; H Lithell; K Hellsing; A M Ostlund-Lindqvist; I B Gustafsson; J Boberg; H Ledermann
Journal:  Atherosclerosis       Date:  1980-10       Impact factor: 5.162

6.  The use of newly synthesized phospholipids for assembly into secreted hepatic lipoproteins.

Authors:  J E Vance
Journal:  Biochim Biophys Acta       Date:  1989-11-06

7.  Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.

Authors:  R E Maxwell; J W Nawrocki; P D Uhlendorf
Journal:  Atherosclerosis       Date:  1983-09       Impact factor: 5.162

8.  Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.

Authors:  B Vessby; H Lithell; I B Gustafsson; J Boberg
Journal:  Atherosclerosis       Date:  1980-01       Impact factor: 5.162

9.  Continuous monitoring of in vitro oxidation of human low density lipoprotein.

Authors:  H Esterbauer; G Striegl; H Puhl; M Rotheneder
Journal:  Free Radic Res Commun       Date:  1989

10.  Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.

Authors:  S J Mao; M T Yates; A E Rechtin; R L Jackson; W A Van Sickle
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

View more
  5 in total

1.  Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.

Authors:  Carl G Gottschalk; Avik Roy; Malabendu Jana; Madhuchhanda Kundu; Kalipada Pahan
Journal:  Mol Neurobiol       Date:  2019-05-24       Impact factor: 5.590

2.  Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.

Authors:  M Vázquez; D Zambón; Y Hernández; T Adzet; M Merlos; E Ros; J C Laguna
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

3.  Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.

Authors:  M Vázquez; N Roglans; A Cabrero; C Rodríguez; T Adzet; M Alegret; R M Sánchez; J C Laguna
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

4.  Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats.

Authors:  G Ozansoy; B Akin; F Aktan; C Karasu
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

Review 5.  Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.

Authors:  Francisco A Monsalve; Radha D Pyarasani; Fernando Delgado-Lopez; Rodrigo Moore-Carrasco
Journal:  Mediators Inflamm       Date:  2013-05-27       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.